New Molecule Shows Promise in Reversing Alzheimer’s in Rats

A research team at the Federal University of ABC (UFABC) in Brazil has developed a novel molecule that demonstrates significant potential in reversing symptoms associated with Alzheimer’s disease in rats. This breakthrough, announced on November 19, 2025, involves a compound that effectively breaks down beta-amyloid plaques by targeting excess copper in the brain, leading to restored memory and reduced inflammation.

Utilizing a combination of advanced computer modeling, laboratory tests, and animal experiments, the researchers have shown that their compound not only protects the brain but also crosses the blood-brain barrier, making it a viable candidate for human trials. The team is actively seeking partnerships with pharmaceutical companies to advance toward clinical testing.

Mechanism of Action: Targeting Copper

The findings, published in the journal ACS Chemical Neuroscience, reveal that the molecule acts as a copper chelator. By binding to excess copper found in beta-amyloid plaques, this compound aids in degrading these toxic structures, which are known to contribute to the cognitive decline seen in Alzheimer’s patients.

Research indicates that copper ions play a crucial role in the aggregation of beta-amyloid plaques, and dysregulation of copper homeostasis can exacerbate the condition. Giselle Cerchiaro, a professor at UFABC and lead researcher, stated, “About a decade ago, international studies began to point to the influence of copper ions as an aggregator of beta-amyloid plaques. Thus, the regulation of copper homeostasis has become one of the focuses for the treatment of Alzheimer’s.”

Development and Testing of the Compound

The research team synthesized ten candidate molecules, with three advancing to in vivo testing in rats with induced Alzheimer’s disease. One compound, in particular, exhibited strong efficacy and safety profiles, forming the basis for the doctoral thesis of Mariana L. M. Camargo, along with the master’s work of Giovana Bertazzo and the undergraduate project of Augusto Farias. Collaborators from the Federal University of São Carlos (UFSCar), led by Kleber Thiago de Oliveira, contributed to the synthesis of one of the key compounds.

In the rat experiments, the treated animals displayed improvements in neuroinflammation and oxidative stress levels. They also showed notable enhancements in spatial navigation and memory tasks. Biochemical analyses confirmed a reversal in beta-amyloid plaque patterns, providing a promising indication of the compound’s potential impact on brain health.

Looking Forward: A Cost-Effective Alternative

With approximately 50 million people globally affected by Alzheimer’s disease and current treatment options often limited and costly, this new molecule could represent a significant advancement in therapy. Current drugs tend to focus on symptom management rather than addressing underlying causes, and many rely on expensive monoclonal antibodies.

The UFABC research team has already filed a patent application for their discovery and is eager to secure industry partnerships to initiate human trials. Cerchiaro emphasized the implications of their work, stating, “It’s an extremely simple, safe, and effective molecule. The compound we’ve developed is much less expensive than available drugs. Therefore, even if it only works for part of the population, it would represent a huge advance over current options.”

As the team moves forward, the medical community watches closely, hopeful that this innovative approach could lead to a breakthrough in the fight against Alzheimer’s disease.